Pilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence
Ключови думи
Резюме
Дати
| Последна проверка: | 01/31/2020 |
| Първо изпратено: | 01/01/2019 |
| Очаквано записване подадено: | 01/02/2019 |
| Първо публикувано: | 01/03/2019 |
| Изпратена последна актуализация: | 02/24/2020 |
| Последна актуализация публикувана: | 02/25/2020 |
| Действителна начална дата на проучването: | 02/07/2019 |
| Приблизителна дата на първично завършване: | 06/14/2021 |
| Очаквана дата на завършване на проучването: | 12/29/2021 |
Състояние или заболяване
Интервенция / лечение
Dietary Supplement: Tart Cherry Concentrate
Фаза
Групи за ръце
| Arm | Интервенция / лечение |
|---|---|
| Experimental: Tart Cherry Concentrate Single arm, open-label design. Commercial Montmorency tart cherry juice concentrate. Servings (1 ounce or 2 tablespoon/serving) per day for three days | Dietary Supplement: Tart Cherry Concentrate Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery |
Критерии за допустимост
| Възрасти, отговарящи на условията за проучване | 50 Years Да се 50 Years |
| Полове, допустими за проучване | All |
| Приема здрави доброволци | Да |
| Критерии | Inclusion Criteria: 1. Males and female patients (age 50-79) at the Mitral Valve Clinic/CVC undergoing elective cardiac surgery for mitral valve repair without the Cox MAZE procedure (MVR patients also undergoing CABG and/or tricuspid valve repair are also eligible) 2. In sinus rhythm (no pre-operative atrial fibrillation, no hx of AF) Exclusion Criteria: 1. Age ≥ 80 years 2. Diagnosed pre-operative chronic or paroxysmal AF 3. Prior ablation procedure for AF 4. Previous cardiac surgery 5. Implanted pacemaker 6. Active smoker 7. Comorbidities such as congenital or cardiac re-operation 8. Use of antiarrhythmic agents 9. Active inflammatory or infectious disease or malignancy 10. Diagnosed autoimmune disease 11. Corticosteroid or other immunomodulatory or immunosuppressive medication 12. Known sensitivity to sorbitol 13. Known gastric sensitivity to acidic juices like orange juice |
Резултат
Първични изходни мерки
1. Patient-reported tolerability score [One week]
2. Efficacy as measured by total number of days in hospital within 60 days of surgery [60 days]
Вторични изходни мерки
1. Time to conversion to normal sinus rhythm [30 days]
2. Heart rhythm at hospital discharge [30 days]
3. Heart rhythm at 30 days [30 days]
4. Need for permanent pacemaker within 30 days of surgery [30 days]
5. Cerebrovascular thromboembolism [stroke, TIA] [30 days]
6. Non-cerebrovascular thromboembolism [30 days]
7. Bleeding [30 days]
8. Cerebrovascular events [30 days]
9. Incidences of postoperative clinical events [30 days]
10. Length of Hospital Stay [60 days]
11. Number of Re-hospitalization and ED visits [60 days]
12. Number of Outpatient Interventions [60 days]
13. Total Costs for Hospital stay [60 days]
